Actuate Therapeutics’ (ACTU) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research note published on Wednesday morning,Weiss Ratings reports.

Several other equities analysts have also issued reports on ACTU. B. Riley began coverage on Actuate Therapeutics in a report on Tuesday, August 26th. They set a “buy” rating and a $20.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Actuate Therapeutics in a report on Tuesday, September 23rd. Finally, Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Actuate Therapeutics Stock Down 3.7%

Shares of ACTU stock opened at $7.79 on Wednesday. The stock’s 50-day moving average is $7.61 and its two-hundred day moving average is $7.92. Actuate Therapeutics has a 1 year low of $5.47 and a 1 year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Hedge Funds Weigh In On Actuate Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ACTU. Chicago Partners Investment Group LLC acquired a new stake in Actuate Therapeutics in the first quarter valued at about $70,000. Sfmg LLC acquired a new stake in Actuate Therapeutics in the first quarter valued at about $74,000. Bank of America Corp DE lifted its position in Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the period. New York State Common Retirement Fund acquired a new stake in Actuate Therapeutics in the second quarter valued at about $105,000. Finally, Northwestern Mutual Wealth Management Co. lifted its position in Actuate Therapeutics by 492.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after purchasing an additional 15,393 shares during the period.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.